Extracorporeal support of the failing liver

Current Opinion in Critical Care

Volumn 8, Issue 2, 2002, Pages 171-177

  Mitzner, Steffen R ^a   Stange, Jan ^a   Peszynski, Piotr ^a   Klammt, Sebastian ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOREACTOR; CELL CULTURE; CONVALESCENCE; DETOXIFICATION; DIALYSIS; EXCHANGE BLOOD TRANSFUSION; EXTRACORPOREAL CIRCULATION; HEMOFILTRATION; HUMAN; LIVER FAILURE; LIVER FUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; NONHUMAN; PLASMAPHERESIS; PRURITUS; REVIEW; SURVIVAL; TECHNIQUE;

BIOREACTORS; EXTRACORPOREAL CIRCULATION; HUMANS; LIVER FAILURE; PLASMA EXCHANGE; SORPTION DETOXIFICATION;

EID: 0036971210     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200204000-00014     Document Type: Review

References (81)

1. Keeffe EB: Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001, 120:749-762.
2. Sterling RK, Fisher RA: Liver transplantation: living donor, hepatocyte, and xenotransplantation. Clin Liver Dis 2001, 5:431-460.
3. Strong RW: Liver transplantation: current status and future prospects. J R Coll Surg Edinb 2001, 46:1-8.
4. Lambrigts D, Sachs DH, Cooper DK: Discordant organ xenotransplantation in primates: world experience and current status. Transplantation 1998, 66:547-561.
5. Kanazawa A, Platt JL: Prospects for xenotransplantation of the liver. Semin Liver Dis 2000, 20:511-522.
6. Cardoso J: Utilization of xenogenic liver in human clinics: tests and perspectives. Pathol Biol (Paris) 2000, 48:362-364.
7. Strom SC, Chowdhury, JR, Fox IJ: Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999, 19:39-48.
8. Malhi H, Gupta S: Hepatocyte transplantation: new horizons and challenges. J Hepatobiliary Pancreat Surg 2001, 8:40-50.
9. Vessey CJ, de la Hall PM: Hepatic stem cells: a review. Pathology 2001, 33:130-141.
10. Allen JW, Hassanein T, Bhatia SN: Advances in bioartificial liver devices. Hepatology 2001, 34:447-455. •• Comprehensive systematic review describing the current status of extracorporeal biologic liver support.
11. Bain VG, Montero JL, de La Mata M: Bioartificial liver support. Can J Gastroenterol 2001, 15:313-318.
12. Davenport A: Artificial hepatic support: where are we now? Blood Purif 2001, 19:1-3.
13. Hayes PC, Lee A: What progress with artificial livers? Lancet 2001, 358:1286-1287.
14. Hui T, Rozga J, Demetriou AA: Bioartificial liver support. J Hepatobiliary Pancreat Surg 2001, 8:1-15.
15. Kaptanoglu L, Blei AT: Current status of liver support systems. Clin Liver Dis 2000, 4:711-729.
16. Nagamori S, Hasumura S, Matsuura T, et al.: Developments in bioartificial liver research: concepts, performance, and applications. J Gastroenterol 2000, 35:493-503.
17. Palmes D, Qayumi AK, Spiegel HU: Liver bridging techniques in the treatment of acute liver failure. J Invest Surg 2000, 13:299-311.
18. Rosenthal P: Is there a future for liver-assist devices? Curr Gastroenterol Rep 2000, 2:55-60.
19. Riordan SM, Williams R: Acute liver failure: targeted artificial and hepatocyte-based support of liver regeneration and reversal of multiorgan failure. J Hepatol 2000, 32(suppl 1):63-76.
20. Sechser A, Osorio J, Freise C, et al.: Artificial liver support devices for fulminant liver failure. Clin Liver Dis 2001, 5:415-430.
21. Sorkine P, Abraham RB, Szold O: Liver support systems. In 2001 Yearbook of Intensive Care and Emergency Medicine. Edited by Vincent JL. Berlin, Heidelberg, and New York: Springer; 2001:619-627.
22. Stockmann HB, Hiemstra CA, Marquet RL, et al.: Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg 2000, 231:460-470.
23. McChesney LP, Fagan EA, Rowell DL, et al.: Extracorporeal liver perfusion. Lancet 1999, 353:120-121.
24. Horslen SP, Hammel JM, Fristoe LW, et al.: Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000, 70:1472-1478.
25. Foley DP, Collins BR, Magee JC, et al.: Bile acids in xenogeneic ex-vivo liver perfusion: function of xenoperfused livers and compatibility with human bile salts and porcine livers. Transplantation 2000, 69:242-248.
26. Pascher A, Sauer IM, Neuhaus P: Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience [abstract]. Hepatology 2001, 34:659A. • Currently the most complete review of whole liver perfusion, giving, for the first time, reliable statistics and independent prognostic markers.
27. Levy MF, Crippin J, Sutton S, et al.: Liver allotransplantation after extracorpo real hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. Transplantation 2000, 69:272-280.
28. Borie DC, Eyraud D, Boleslawski E, et al.: Functional metabolic characteristics of intact livers during prolonged extracorporeal perfusion: potential for a unique biologic liver-assist device. Transplantation 2001, 72:393-405.
29. Kiley JE, Pender J, Welch HF, et al.: Ammonia intoxication treated by hemo-dialysis. N Engl J Med 1958, 259:1156-1161.
30. Gazzard BG, Weston MJ, Murray-Lyon IM, et al.: Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1974, 1:1301-1307.
31. O'Grady JG, Gimson AE, O'Brien CJ, et al.: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988, 94:1186-1192.
32. Nyberg SL, Peshwa MV, Payne WD, et al.: Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg 1993, 166:512-521.
33. Malchesky PS: Nonbiologic liver support: historic overview. Artif Organs 1994, 18:342-347.
34. Mitzner S, Stange J: Cell-free artificial liver support: a critical review. In Current Aspects and Concepts of Nursing, Coordinating, Bridging and Rehabilitation in Organ Transplantation. Edited by Körner MM, Körfer R. Amsterdam: Elsevier Science BV; 1995:81-88.
35. Busse B, Smith MD, Gerlach JC: Treatment of acute liver failure: hybrid liver support: a critical overview. Langenbecks Arch Surg 1999, 384:588-599.
36. Stange J, Ramlow W, Mitzner S, et al.: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993, 17:809-813.
37. Mitzner S, Stange J, Klammt S, et al.: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, controlled clinical trial. Liver Transplantation 2000, 6:277-286. • First published randomized, clinical trial using MARS. It showed significant survival prolongation in a particularly ill subgroup of patients with hepatorenal syndrome type 1. See comments in Mullen KD, Treatment of hepatorenal syndrome: lessons from the MARS trial. Hepatology 2002, 35:492-493.
38. Stange J, Mitzner S, Klammt S, et al.: New extracorporeal liver support for chronic liver disease complicated by cholestasis: results of a prospective, controlled, randomized two center trial [abstract]. J Hepatol 2001, 34(suppl 1):45. • Controlled trial of the Albumin Dialysis MARS compared with standard care in 24 patients with decompensated chronic hepatic failure with progressive cholestasis. The 30-day survival was considerably improved in the MARS group (92% vs 50%).
39. El-Banayosy A, Kizner L, Notohamiprodjo M, et al.: Single center randomized study to evaluate MARS technique on patients with hyperbilirubinemia following cardiogenic shock after cardiac surgery [abstract]. In Abstract Book, 3rd International Symposium on Albumin Dialysis in Liver Disease, September 7-9, 2001, Rostock, Germany. Hamburg, Germany: Nutius Marketing Logistik; 2001. • An interim analysis of a controlled trial of the Albumin Dialysis MARS in patients with liver failure after cardiac surgery that reports significant in-hospital survival in the MARS group (six of eight) compared with standard care (one of nine).
40. Mitzner S, Stange J, Klammt S, et al.: Extracorporeal detoxification using the Molecular Adsorbent Recirculating System for critically ill patients with liver failure. J Am Soc Nephrol 2001, 12:S75-S82.
41. Mitzner S, Stange J, Klammt S, et al.: Albumin dialysis using the MARS system. Curr Opin Nephrol Hypertens 2001, 10:777-783. • Current review of the literature on the Albumin Dialysis MARS.
42. Awad SS, Swaniker F, Magee J, et al.: Results of a phase I-trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001, 130:354-362. This is the first US-based report of the use of albumin dialysis in a prospective trial in FHF (United Network for Organ Sharing [UNOS] 1) and acute decompensation of chronic hepatic failure with severe complications (UNOS VII). It reports significant improvement in liver synthesis and detoxification. The first report of a successful bridging of an anhepatic patient to liver transplantation.
43. Schmidt LE, Sorensen VR, Svendsen LB, et al.: Hemodynamic changes during a single treatment with the Molecular Adsorbent Recircutating System in patients with acute-on-chronic liver failure. Liver Transplantation 2001, 7:1034-1039.
44. Novelli G, Rossi M, Pretagostini R, et al.: Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Transplant Proc 2001, 33:1942-1944.
45. Sorkine P, Ben Abraham R, Szold O, et al.: Role of the Molecular Adsorbent Recycling System (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001, 29:1332-1336.
46. Zakaria N, Wendon J, Creamer D, et al.: Albumin dialysis (MARS device) relieves cholestatic pruritus in a dramatic but non-sustained manner [abstract]. Hepatology 2001, 34:550A
47. Ash SR, Blake DE, Carr DJ, et al.: Neurologic improvement of patients with hepatic failure and coma during sorbent suspension dialysis. ASAIO Trans 1991, 37:M332-M334.
48. Wilkinson AH, Ash SR, Nissenson AR: Hemodiabsorption in treatment of hepatic failure. J Transpl Coord 1998, 8:43-50. • Controlled trial of the BioLogicDT in 11 patients with hepatic failure and hepatic encephalopathy. Reports improved outcome compared with standard care.
49. Hughes RD, Pucknell A, Routley D, et al.: Evaluation of the BioLogic-DT sorbent-suspension dialyzer in patients with fulminant hepatic failure. Int J Artif Organs 1994, 17:657-662. • This controlled trial of the BioLogicDT in 10 patients with FHF and hepatic encephalopathy grade IV failed to show significant difference in survival compared with standard care.
50. Ellis AJ, Hughes RD, Nicholl D, et al.: Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Int J Artif Organs 1999, 22:27-34. • A controlled trial of the BioLogicDT in ten patients with alcoholic hepatitis and severe encephalopathy, which showed good biocompatibility and a decrease in ammonia in the DT group. However, there were no survivors in either group.
51. Kramer L, Gendo A, Madl C, et al.: Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis 2000, 36:1193-1200. • Controlled trial of the BioLogicDT in 20 patients with decompensated cirrhosis and hepatic encephalopathy grade II or III.
52. Kramer L, Gendo A, Madl C, et al.: A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathy. Int J Artif Organs 2001, 24:434-442. • Controlled trial of the BioLogicDT in 20 patients with decompensated cirrhosis and hepatic encephalopathy grade II or III. Reports significant improvement in evoked potentials but not in hepatic encephalopathy.
53. Ash SR, Steczko J, Knab WR, et al.: Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic-DTPF system. Ther Apher 2000, 4:218-228.
54. Clemmesen JO, Larsen FS, Ejlersen E, et al.: Haemodynamic changes after high-volume plasmapheresis in patients with chronic and acute liver failure. Eur J Gastroenterol Hepatol 1997, 9:55-60.
55. Clemmesen JO, Kondrup J, Nielsen LB, et al.: Effects of high-volume plasma-pheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol 2001, 96:1217-1223.
56. Yoshiba M, Inoue K, Sekiyama K, et al.: Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs 1996, 20:1169-1172. • Large group (N = 67) of viral hepatitis-induced FHF patients treated with combined plasma exchange and continuous hemodiafiltration. This study reports 97% of reversal in hepatic encephalopathy and 55% survival without liver transplantation.
57. Okamoto K, Kurose M, Ikuta Y, et al.: Prolonged artificial liver support in a child with fulminant hepatic failure. ASAIO J 1996, 42:233-235.
58. Kawagishi N, Ohkohchi N, Fujimori K, et al.: Experience with artificial liver support in 16 living related liver transplant recipients. Ther Apher 2001, 5:7-11.
59. Rozga J, Podesta L, LePage E, et al.: A bioartificial liver to treat severe acute liver failure. Ann Surg 1994, 219:538-546.
60. Stevens AC, Busuttil R, Han S, et al.: An interim analysis of a phase II/III prospective, randomized, multicenter, controlled trial of the HepatAssist bio-artificial liver support system for the treatment of fulminant hepatic failure [abstract]. Hepatology 2001, 34:299A. •• Largest reported controlled trial in the field of extracorporeal liver support (N = 171). Showed significant survival advantage in the subgroup of FHF undergoing liver transplantation. Failed to reach significance in the total study population, in the total FHF groups and the PNF group.
61. Gerlach J: Development of a hybrid liver support system: a review. Int J Art Org 1996, 19:645-654.
62. Gerlach J: Modular extracorporeal liver support system (MELS) [International Liver Support Registry Website]. Available at: http://www.ilsr.net. Accessed January 2, 2002.
63. Kardassis D, Sauer IM, Obermayer N, et al.: Initial clinical experience in hybrid liver support, utilising primary human liver cells [abstract]. Liver Transplantation 2001, 7:C60.
64. Sussman NL, Gislason GT, Kelly JH: Extracorporeal liver support: application to fulminant hepatic failure. J Clin Gastroenterol 1994, 18:320-324.
65. Ellis AJ, Hughes RD, Wendon JA, et al.: Pilot-controlled trial of the extracor- poreal liver assist device in acute liver failure. Hepatology 1996, 24:1446-1451. • Only controlled trial with the ELAD. Here the support system failed to show superiority to standard care.
66. Millis JM, Cronin DC, Conjeevaram HS, et al.: Improvement of hemodynamic parameters in fulminant hepatic failure patients with extracorporeal liver assist device (ELAD) treatment [abstract]. Hepatology 2000, 32:613A.
67. Flendrig LM, la Soe JW, Jorning GG, et al.: In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997, 26:1379-1392.
68. Flendrig LM, Calise F, Di Florio E, et al.: Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver. Int J Artif Organs 1999, 22:701-709.
69. Chamuleau RAFM: AMC: bioartificial liver (International Liver Support Registry Web site). Available at: http://www.ilsr.net. Accessed January 2, 2002.
70. Patzer JF, Mazariegos GV, Lopez R, et al.: Novel bioartificial liver support system: preclinical evaluation. Ann N Y Acad Sci 1999, 875:340-352.
71. Mazariegos GV, Kramer DJ, Lopez RC, et al.: Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J 2001, 47:471-475.
72. Nyberg SL, Shirabe K, Peshwa MV, et al.: Extracorporeal application of a gel-entrapment, bioartificial liver: Demonstration of drug metabolism and other biochemical functions. Cell Transplant 1993, 2:441-452.
73. Sielaff TD, Nyberg SL, Rollins MD, et al.: Characterization of the three-compartment gel-entrapment porcine hepatocyte bioartificial liver. Cell Biol Toxicol 1997, 13:357-364.
74. Nyberg S: Cross-species transmission of PERV appears unlikely. Liver Transplantation 2000, 6:115-117.
75. Kuddus R, Patzer JF, Lopez R, et al.: Valuation of transmission of porcine endogenous retrovirus into patients subjected to hemoperfusion using an extracorporeal bioartificial liver support system. Transplant Proc 2001, 33:1976.
76. Pitkin Z, Mullon C: Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999, 23:829-833.
77. Kobayashi N, Fujiwara T, Westerman KA, et al.: Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000, 287:1258-1262. •• Perhaps the most advanced data on immortalization of human hepatocytes, thought to be the ideal cell source for extracorporeal liver support.
78. Cascio SM: Novel strategies for immortalization of human hepatocytes. Artif Organs 2001, 25:529-538.
79. Faris RA, Konkin T, Halpert G: Liver stem cells: a potential source of hepatocytes for the treatment of human liver disease. Artif Organs 2001, 25:513-521. • Informative review listing current knowledge about liver stem cells with focus on potential use in extracorporeal therapy, for example. Such use may represent the future or the end of extracorporeal liver support.
80. Naumann G, Obermayer N, Kardassis D, et al.: Analysis of 31 liver transplant discards as cell source for hybrid liver support [abstract]. Liver Transplantation 2001, 7:C61.
81. Liu J, Jauregui HO, Faris RA, et al.: Growth and metabolic activity of immortalized porcine hepatocytes in extracorporeal hollow-fiber liver assist devices. Artif Organs 2001, 25:539-545.